Reata Pharmaceuticals Stock is Flying High
Here is another example of why analysts can no longer use the same old measures to evaluate the biotechnology firms. They cannot continue to ignore the values of the firms’ technologies and very promising products. Very promising products are those that can treat diseases in patients who are condemned with a diagnosis. Today’s example is flying on the wings of Reata Pharmaceuticals’ (This content is for paid subscribers.